drugset / Trial / NCT03056209
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.
Timeline
- Start
- 2017-06-26
- Primary completion
- 2018-04-16
- Completion
- 2018-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Napazimone | Small molecule | 25 mg | Oral |
| Subject | Napazimone | Small molecule | 50 mg | Oral |
| Subject | Napazimone | Small molecule | 100 mg | Oral |
| Subject | Napazimone | Small molecule | 200 mg | Oral |
| Subject | Napazimone | Small molecule | 400 mg | Oral |
| Subject | Napazimone | Small molecule | 600 mg | Oral |
| Subject | Napazimone | Small molecule | 800 mg | Oral |